Group | Source | Vγ9/Vδ2 EF after In Vitro Culture with | ||||
---|---|---|---|---|---|---|
Rib-1-P | Xyl-1-P | IPP | DMAPP | TUBAg | ||
TBM patients | ||||||
1 | CSF | 14 | 13 | 24 | 28 | 35 |
PBMC | 7 | 2 | 5 | 6 | 8 | |
2 | CSF | 38 | 30 | 61 | 54 | 68 |
PBMC | 22 | 12 | 30 | 28 | 40 | |
3 | CSF | 15 | 10 | 40 | 30 | 64 |
PBMC | 10 | 8 | 32 | 26 | 44 | |
4 | CSF | 17 | 21 | 44 | 49 | 79 |
PBMC | 12 | 20 | 45 | 53 | 72 | |
5 | CSF | 35 | 27 | 60 | 48 | 90 |
PBMC | 20 | 18 | 34 | 40 | 54 | |
6 | CSF | 15 | 17 | 78 | 80 | 143 |
PBMC | 7 | 12 | 12 | 18 | 32 | |
Controls | ||||||
7 | CSF | 1 | 3 | 1 | 7 | 5 |
PBMC | 1 | 1 | 2 | 4 | 5 | |
8 | CSF | 3 | 1 | 2 | 10 | 5 |
PBMC | 1 | 1 | 6 | 4 | 7 | |
9 | CSF | 5 | 2 | 1 | 6 | 8 |
PBMC | 6 | 7 | ND | ND | 5 | |
10 | CSF | 3 | 7 | 7 | 4 | 2 |
PBMC | 1 | 4 | 5 | 5 | 12 | |
11 | CSF | 2 | 3 | 1 | 9 | 11 |
PBMC | 2 | 4 | 4 | 7 | 7 | |
12 | CSF | 5 | 6 | 8 | 8 | 11 |
PBMC | 6 | 4 | 7 | 9 | 9 | |
13 | CSF | 1 | 4 | 5 | 3 | 5 |
PBMC | 3 | 7 | 7 | 9 | 14 |